摘要:
A gas valve assembly may include a valve body with one or more valves movable between an opened position and a closed position, one or more valve actuators configured to operate the valves, and one or more pressure sensors to sense a pressure within a fluid path of the valve assembly. A valve controller may receive a measure related to a sensed pressure from the one or more pressure sensor(s). The valve controller may compare the received measure related to the sensed pressure to an overpressure threshold. In the event the measure related to the sensed pressure surpasses the overpressure threshold value, the valve controller may be configured to provide a signal that indicates an overpressure event has occurred.
摘要:
A gas valve assembly may include an electronic valve controller secured relative to a valve body. The electronic controller may be configured to count each operational cycle of the gas valve and maintain a cumulative count of the number of operational cycles experienced by the gas valve in a memory, such as a non-volatile memory. In some cases, the non-volatile memory may also store one or more operational cycle threshold values that may be retrieved and compared to the cumulative count of the number of operational cycles experienced by the gas valve. In some instances, where the cumulative count of the number of operational cycles experienced by the gas valve meets and/or exceeds the threshold number of operational cycles, the gas valve may be prevented from opening.
摘要:
A system having unified diagnostics where an electrical energy storage device may supply an actuator. Various techniques may be used to determine energy storage capacity and actuator current usage. Measured storage capacity and actuator current may indicate the health of the energy storage device and the actuator, respectively. Also, operation of a service switch for the actuator may be checked relative to its state.
摘要:
The present disclosure relates to p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and to its use in treating conditions such as viral infections, tumors, and cancer. Also disclosed is a method of preparing the p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and methods for producing furanose compounds which are useful intermediates in the preparation of pharmaceutical compounds such as p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and the like.
摘要:
The present disclosure relates to p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and to its use in treating conditions such as viral infections, tumors, and cancer. Also disclosed is a method of preparing the p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and methods for producing furanose compounds which are useful intermediates in the preparation of pharmaceutical compounds such as p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and the like.
摘要:
The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
摘要:
Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
摘要:
Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
摘要:
This disclosure relates generally to valves, and more particularly, to gas valve assemblies. In one example, the valve assembly may include a valve body with an inlet port, an outlet port, and a fluid path extending between the inlet and outlet ports, one or more valves situated about the fluid path, one or more valve actuators for selectively moving respective valves, one or more sensors for sensing one or more parameters within the fluid path, and a controller secured relative to the valve body and in communication with the one or more sensors for determining one or more valve assembly conditions based on the one or more sensed parameters. Illustratively, the controller may be configured to communicate information from the valve assembly to a combustion appliance controller that is located remotely from the valve assembly through a communications interface of the controller and across a communications bus.
摘要:
This disclosure relates generally to valves, and more particularly, to gas valve assemblies. In one example, the valve assembly may include a valve body with a fluid path, one or more valves or valve sealing members positioned across the fluid path, and one or more pressure sensors in fluid communication with a fluid path of the valve assembly. The valve assembly may include a valve controller in communication with the pressure sensors, where the valve controller may be configured to compare a measure related to a pressure sensed by the one or more pressure sensors to a pressure threshold value (e.g., a high pressure threshold value, a low pressure threshold value, or other pressure threshold value). If the measure surpasses the threshold value, the valve controller may provide a predetermined output signal indicating a pressure event has occurred, such as a high or low gas pressure event.